GSK Pulls Regulatory Filings for Anti-Nausea Drug

GlaxoSmithKline (GSK) is discontinuing all regulatory filings for the casopitant drug it was developing for chemotherapy-induced and postoperative nausea and vomiting, citing safety data requirements in a June FDA complete response letter. The company determined that additional safety data would be needed to support worldwide registration of casopitant, to be sold in the U.S. as Rezonic, GSK spokeswoman Sarah Alspach said. GSK has no further plans to develop the drug.
Drug Industry Daily